HR Execs on the Move

Gennao Bio

www.gennao.com

 
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.gennao.com
  • 311 Pennington Rocky Hill Road Building 21
    Hopewell, NJ USA 08534
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

TEK Solutions Inc

TEK Solutions Inc is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMD Serono

EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany, employing over 1,200 individuals around the country with U.S. headquarters located in Rockland, Massachusetts. The company develops and offers therapies for specialty-care conditions, like multiple sclerosis, infertility and cancer. EMD Serono is committed to transforming lives by developing therapies that patients need and providing industry-leading educational and support programs.

Nocion Therapeutics

NOCION is a biopharmaceutical company that is addressing vexing medical problems head on. We are developing `nocions`—a new kind of therapy that selectively affects actively firing nocioceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.

Hound Labs

Hound Labs combines science and technology in novel ways to improve health and wellness. The Company believes its ultra-sensitive and portable technologies will pave the way to practical and fair solutions for some of the leading public health and safety issues. In the coming month, Hound Labs will launch the HOUND® CANNABIS BREATHALYZER, which allows employers and law enforcement to identify recent cannabis in breath. Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, founded Hound Labs in 2014.

MBX Biosciences

MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.